acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

General

Allurion Technologies, Inc. (&quot;Allurion&quot; or the &quot;Company&quot;) (NYSE:ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with

Allurion Announces Clinical Study Combining Allurion Program And GLP-1 Agonists To Improve Muscle Mass, Studies Show 5.6% Muscle Gain And 14% Weight Loss Over 4 Months With Allurion Balloon; In Another Study Of 167 Patients, Patients Treated With The Allurion Balloon Experienced A Weight Reduction Of 15.7% With No Change In Muscle Mass. - Allurion Technologies (NYSE:ALUR)

Benzinga Newsdesk

Allurion Technologies

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with

ALUR

Allurion Announces Clinical Study Combining Allurion Program And GLP-1 Agonists To Improve Muscle Mass, Studies Show 5.6% Muscle Gain And 14% Weight Loss Over 4 Months With Allurion Balloon; In Another Study Of 167 Patients, Patients Treated With The Allurion Balloon Experienced A Weight Reduction Of 15.7% With No Change In Muscle Mass.

Comments